Addex Therapeutics Ltd - ADR
NASDAQ:ADXN
| Market Cap (Intraday) | 20.52M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 3.86 |
| 10-Day MA | $21.65 |
| 50-Day MA | $13.85 |
| 200-Day MA | $9.62 |
Addex Therapeutics Ltd - ADR Stock, NASDAQ:ADXN
9, Chemin des Mines, Plan-les-Ouates, Geneva, Geneve (Geneva) 1202
Switzerland
Phone: +41.22.884.15.55
Number of Employees:
Description
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.